Cancer and heart failure (HF) are common medical conditions with a steadily rising prevalence in industrialized countries, particularly in the elderly, and they both potentially carry a poor prognosis. A new diagnosis of malignancy in subjects with pre-existing HF is not infrequent, and challenges HF specialists as well as oncologists with complex questions relating to both HF and cancer management. An increased incidence of cancer in patients with established HF has also been suggested. This review paper summarizes the epidemiology and the prognostic implications of cancer occurrence in HF, the impact of pre-existing HF on cancer treatment decisions and the impact of cancer on HF therapeutic options, while providing some practical suggestions regarding patient care and highlighting gaps in knowledge.
Introduction
The population of industrialized countries is progressively ageing, and older age predisposes to alterations in cardiac structure and function that may culminate with heart failure (HF), especially HF with preserved left ventricular ejection fraction (LVEF).
1,2 Furthermore, major advances in treatment have led to a dramatic reduction in short-term mortality following acute myocardial infarction and other acute cardiovascular events, but have not influenced to the same extent the subsequent adverse myocardial remodelling that often leads to HF with reduced LVEF (HFrEF). 3 As a result, HF is a syndrome with steadily growing prevalence and largely affecting elderly individuals. 4 Accordingly, in 2014 the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) published a White Paper, already endorsed by 49 national HF working groups, stressing the burden of HF with a clear call to action to promote prevention, improve disease awareness, ensure equity of care, support patients and their caregivers, and foster research. The incidence of most cancers also increases with age. 5 According to the last American Cancer Society estimates, the probability of developing invasive cancer at any site is 1 in 19 and 1 in 29 for females and males, respectively, from birth to 49 years of age. It increases to 1 in 17 and 1 in 15 during the sixth decade of life, becomes 1 in 10 and 1 in 7 in the seventh decade, and reaches 1 in 4 and 1 in 3 after 70 years of age. 6 Within this epidemiological framework, diagnosis of cancer is not infrequent in patients with HF, and it has recently been reported that malignancies are actually detected more often in subjects with HF than in the general population. 7 -9 Surprisingly, however, the problem of malignancies in patients with pre-existing HF has been far less discussed than the one of HF secondary to the cardiotoxicity of anti-neoplastic treatments. In fact, cancer is often not considered among the co-morbidities that may be associated with and impinge on HF management and outcomes, 10 in part due to the fact that subjects with cancer are usually excluded from HF randomized controlled trials.
While knowledge of the cardiotoxicity of oncological therapies is important, 11 the Cardio-Oncology Study Group of the HFA of the ESC calls for efforts to better characterize the burden of incident cancer in pre-existing HF and to promote comprehensive actions, accounting both diseases rather than focusing on one. These initiatives should include well-designed studies specifically addressing the occurrence of malignancies in HF, which have been limited in number so far, with the goal of having solid data in support of the recommendations for management of cancer in HF, rather than expert opinions based on clinical experience as it is at present. This paper was endorsed by the Cardio-Oncology Study Group of the HFA of the ESC and was initially conceived in a meeting held during the 2016 HFA Congress of the ESC in Florence, Italy. The following issues were identified as especially relevant and are discussed below: Incidence of cancer in heart failure: facts and theories
The incidence of cancer in established HF has been estimated to be in the range of 18.9-33.7 per 1000 person-years by retrospective analyses. 7 -9 These studies have consistently reported a higher risk of malignancy in subjects with HF than in non-HF controls, despite differences in the cohorts evaluated, the definition of cancer, and the statistical methods applied. This finding may be due to a surveillance bias, since active follow-up of HF patients with regular visits may result in detection of tumours at an early stage, which is missed in the general population.
7 -9 Silent malignancies may be discovered by exams routinely performed for HF management (e.g. red blood cell count revealing anaemia due to primary or secondary neoplastic infiltration of the bone marrow, or chest X-ray showing a pulmonary nodule). It is also possible that HF therapies render clinically overt tumours that would be otherwise asymptomatic: this may be for instance the case with prostate carcinoma being revealed by difficult voiding in response to diuretics, or intestinal neoplasms that start to bleed due to chronic anti-thrombotic treatment. Strikingly, these scenarios are well known by clinical practice, but have not actually been put in evidence by the scientific literature. On the other hand, symptoms due to a tumour may overlap with those of HF and be attributed to heart disease. This may even delay cancer diagnosis, as symptoms might be thought of as due to advancing disease rather than new cancer.
12,13
The association between HF and cancer may otherwise be the consequence of shared risk factors: besides ageing, many habits and conditions predispose to both HF and cancer, e.g. cigarette smoking, inactivity and obesity. 14, 15 It has also been hypothesized that HF itself may promote carcinogenesis through mechanisms yet to be characterized. For instance, the tumorigenic role of HF-related low-grade inflammation has been suggested, 7, 9 and hyperactivity of the sympathetic nervous system and the renin-angiotensin system may also drive malignancy.
16,17
Meta-analyses of randomized controlled trials and population studies have revealed a positive correlation between treatment with medications that may be used for HF, especially angiotensin receptor blockers and digoxin, 18, 19 and risk of cancer; however, these results have been refuted by other investigators. 20, 21 A major problem in interpretation of these data is the competing risk issue: if HF patients receive life-saving therapies, development of malignancies has more 'opportunity' and patients may paradoxically be diagnosed with cancer more frequently. 22 Nevertheless, there are also theories that specific HF drugs may exert anti-tumour effects. In metastatic renal cell carcinoma, a better progression-free survival was observed for patients taking angiotensin-converting enzyme (ACE) inhibitors (often for pre-existing or cancer therapy-induced arterial hypertension) compared to other anti-hypertensive drugs, and experimental work indicates that ACE inhibitors may potentiate the efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors against renal Figure 1 Cancer and heart failure carry an independent risk of mortality, but also potentially hinder the treatment of one another, with the result being a further increase in mortality. CIED, cardiac implantable electronic device; ICD, implantable cardioverter-defibrillator; LVAD, left ventricular assist device; RT, radiation therapy. carcinoma cells. 23 Several cancer cells express -adrenergic receptors on the surface membranes and their proliferation is increased after catecholamine exposure, 24 making them potentially treatable with beta-blockers. Moreover, -adrenergic receptors may interact with other membrane receptors with oncogenic activity, such as human epidermal growth factor receptor 2 (HER2). 25 A number of trials of beta-blockers to modify cancer outcomes are currently underway, with an analysis of cancer registry data pointing to the fact that 2-, but not 1-adrenergic receptor blockade, may reduce breast cancer-specific mortality. 26 Statins have also been accused of increasing cancer incidence, but this hypothesis has recently been rejected.
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Outcomes for heart failure patients diagnosed with cancer
The prognosis of HF is dismal. A recent analysis of a database of 1.75 million people from primary care practices in Scotland, of which more than 50 000 had HF, showed that 5-year survival of patients with HF was lower than the one of patients with common malignancies, namely of the prostate and bladder for men and of the breast for women. 28 Outcomes may be even worse when cancer is superimposed on pre-existing HF, with epidemiological data indicating that HF patients who are diagnosed with cancer have higher all-cause mortality than both subjects with HF but no . 9 This partly reflects the increased risk of death that HF and cancer carry independently from each other, but it is also likely the result of the negative impact that each condition has on management of the other one ( Figure 1) . Indeed, cancer has been found to increase the risk of HF readmission after a first HF hospitalization, similar to other co-morbidities such chronic kidney disease or diabetes mellitus.
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Challenges in cancer therapy for patients with pre-existing heart failure
Limitations in the tolerability of anti-neoplastic treatments
Heart failure is characterized by a reduced cardiovascular reserve, which may be further impaired by cancer, possibly by aggravating systemic inflammatory activation and endothelial dysfunction. It was recently reported that subjects with colorectal cancer, but no overt cardiovascular disease, display subtle alterations in cardiac and autonomic nervous system function, contributing to a decrease in exercise capacity. 30 Furthermore, common complications of malignancies, like electrolyte and water loss or hormonal imbalance, may impinge on cardiovascular homeostasis. 31 Even increased heart rate has been found to be associated with poor survival in patients with advanced malignancies. 32 As a result, the ability of patients with HF to withstand oncological surgery, medical therapy or radiotherapy is often limited, and this may be critical when a tumour requires aggressive management. In a recent Medicare-based analysis of almost 100 000 cases of non-small cell lung cancer, the risk of death was increased by concomitant HF at baseline for any combination of surgery, chemotherapy or radiotherapy. 33 Remarkably, HF was present in 14-22% of subjects at the time of lung cancer diagnosis, confirming that occurrence of cancer in individuals with pre-existing HF is not rare.
Concerns with potentially cardiotoxic drugs
Many oncological therapies are cardiotoxic and the balance between their anti-tumour activity and cardiac side effects should be carefully assessed by a specialist before administering them to patients with known HF. 34 For some drugs, such as anthracyclines, 5-fluorouracil and capecitabine, the HER2 targeting antibody trastuzumab, and VEGF-directed tyrosine kinase inhibitors, the potential of cardiac damage is particularly high. 35 These drugs can cause (or aggravate) left ventricular systolic or diastolic dysfunction and may precipitate myocardial ischaemia and arrhythmias by a variety of mechanisms (Table 1) . 36, 37 Hence, their use in patients with pre-existing HF must be extremely cautious, justified by the benefit to cancer outcomes and the absence of alternative oncological treatments, and with appropriate informed consent and close surveillance with clinical assessment, cardiac imaging and biomarkers. This is even more so considering that there is paucity of data about these medications in HF.
Other oncological therapies may increase the risk of vascular events that could have a secondary impact on HF. These include gonadotropin-releasing hormone (GnRH) agonists and anti-androgens, used to treat locally advanced and metastatic prostate cancer, VEGF tyrosine kinase inhibitors for various solid tumours and BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukaemia. Growing evidence shows that GnRH agonists increase the risk of ischaemic heart disease and HF hospitalization, potentially due to increased vascular inflammation, increases in LDL-cholesterol and development of insulin resistance, 38, 39 which are predicted to disrupt pre-exiting vascular disease and accelerate development of de novo vascular disease. Cardiologists, oncologists and urologists should be aware of these side effects of androgen deprivation therapy, which is often viewed as a safe treatment as compared with chemotherapy, since many endocrine and metabolic changes secondary to low androgen levels occur slowly and the development and presentation of cardiovascular toxicity is over a longer timeframe.
Traditional HF treatments, such as angiotensin and -adrenergic receptor blockade, have been proposed as a strategy to preserve LVEF in subjects without HF receiving anthracyclines and/or trastuzumab, but so far results of randomized clinical trials have been discordant. 40 targeting the renin-angiotensin-aldosterone system are the mainstay of medical treatment and should be prescribed irrespective of chemotherapy. Nonetheless, specific molecules within each of these pharmacological classes might be particularly protective against the toxicity of anti-neoplastic therapies: one example is carvedilol, which may be more effective than selective 1-adrenergic receptor blockers in counteracting cardiomyocyte oxidative stress induced by anti-cancer drugs according to in vitro studies. 42 However, there are no clinical data confirming this experimental evidence.
Preparing patients with heart failure for anti-tumour therapies
Once a cancer treatment protocol suitable for a patient with HF is identified, baseline review by a HF specialist or Cardio-Oncology service is essential to take general cardioprotective measures and improve HF management prior to starting anti-neoplastic therapy ( Figure 2) .
The first goal is to eliminate or reduce residual major cardiovascular risk factors, such as smoking, dyslipidaemia, arterial hypertension and diabetes, through evidence-based and guideline-approved lifestyle and pharmacological approaches.
Some co-morbidities including chronic obstructive pulmonary disease and diabetes are common among the HF population, but can be effectively treated if recognized. 29, 43, 44 Depression should not be neglected not only because it may impair quality of life and may lead to non-adherence to HF therapy, 45 but also because it may result in the loss of motivations to cope with cancer diagnosis and treatment. The Beck Depression Inventory and Cardiac Depression Scale have been formally validated as reliable tools for the evaluation of depressive mood in patients with HF. 46 Understanding the risks of the cancer therapies scheduled for the HF patient with new diagnosis of cancer is of paramount importance, since every medication has its own panel of cardiovascular side effects (left ventricular dysfunction, hypertension and vascular toxicities, thrombosis, ischaemia, QT prolongation and arrhythmias), and prompt correction of conditions which may exacerbate such toxicities, e.g. electrolyte disturbances, is fundamental. 34 In the context of optimizing HF management, re-evaluation of the status and underlying cause of HF is advisable before proceeding to oncological therapies. A detailed baseline assessment with clinical review, ECG, cardiac biomarkers and cardiac imaging can help in defining the further treatment. In HF due to coronary heart disease, provocative testing may be required to exclude any residual myocardial ischaemia in symptomatic patients; stress echocardiography is generally preferred in order to avoid radiation but in selected cases, e.g. poor echo windows, myocardial scintigraphy is appropriate. 34 If valvular heart disease is the aetiology of HF, the degree of valvular stenosis or regurgitation should be re-assessed: if it is severe, multidisciplinary discussion with the heart team is advocated in order to determine whether correction of the valve disease should be attempted before the patient receives anti-cancer treatments. Stress echocardiography may help in risk stratification of asymptomatic, but severe valvular dysfunction. 47 The possibility The highest frequency reported in the literature are presented in the Table. For more detailed information about the incidence of anti-cancer therapy cardiotoxicity, see Zamorano et al. 34 HER2, human epidermal growth factor receptor 2; HFrEF, heart failure with reduced ejection fraction; LVSD, left ventricular systolic dysfunction; TKI, tyrosine kinase inhibitors; VEGF, vascular endothelial growth factor.
of cardiac resynchronization therapy (CRT) should be discussed in the case of HFrEF with untreated left bundle branch block, even if minimally symptomatic. 48 In this regard, it is interesting to note that in a contemporary HF cohort in Sweden cancer in the last 3 years was not associated with omission of CRT, suggesting that cardiologists are not discouraged by a history of malignancy when considering CRT. 49 Nonetheless, all these decisions are mostly based on opinion as there is a lack of evidence from randomized controlled trials and registries to guide decision-making.
Achievement of optimal HF management may require months for initiation and potentiation of HF medication and device interventions, with possible delays in cancer surgery or systemic anti-neoplastic treatment. The time required to maximize medical therapy, including up-titration of ACE inhibitors and beta-blockers in HFrEF patients, and the choice of pursuing advanced device therapies, requires an informed discussion between HF specialists or cardio-oncologists and oncologists to compare the choices-starting cancer treatment whilst HF is sub-optimally treated vs. deferring cancer treatment. More rapid up-titration strategies can be considered with cautious implementation and regular review by the HF team if cancer treatments cannot be delayed for prognostic reasons. Again, however, there is no evidence supporting physicians facing these issues, and more research is required to fill these gaps in knowledge.
. 
Following patients with heart failure during cancer therapy
Regular cardiovascular monitoring of subjects with HF receiving oncological treatments is strongly advised, in order to detect early signs of decompensation or cardiotoxicity and institute additional measures or discuss temporary or permanent interruption of cancer therapy if necessary (Figure 2 ). More frequent monitoring compared to the standard 'guideline' strategy may be necessary, using cardiac imaging and biomarkers like natriuretic peptides. 50 Special attention should be given to specific cardiovascular side effects of oncological therapies, e.g. hypertension or ischaemia in tyrosine kinase inhibitor recipients. 51 Many systemic anti-neoplastic drugs, both cardiotoxic and non-cardiotoxic, are frequently prescribed with large amounts of concomitant intravenous fluid to minimize nephrotoxicity. Care must be given in patients with pre-existing HF who are prone to fluid retention, and where possible the total volume administered should be reduced, the infusion time prolonged, and diuretics added to enhance diuresis and reduce the risk of congestion. 34 Clinical surveillance should also include interrogation of cardiac implantable electronic devices (CIED) before and after radiotherapy, because of the possibility of dysfunction or damage by scattered radiation. 52 Direct CIED irradiation and high-energy (>10 MV) or neutron-producing beams should be avoided, and Figure 2 While management of heart failure (HF) and various types of cancer relies on detailed evidence-based guidelines, much less data are available to inform the decisions of physicians caring a patient with HF who is also diagnosed with a malignancy. Key issues that should be taken into account are presented in the Figure. CIED, cardiac implantable electronic device; CRT, cardiac resynchronization therapy; CV, cardiovascular; ICD, implantable cardioverter-defibrillator; IHD, ischaemic heart disease; LVAD, left ventricular assist device; RT, radiation therapy; VHD, valvular heart disease. *Treatment of IHD and VHD must also meet the criteria of current guidelines. # Presence of a potentially treatable cardiac electrical dyssynchrony is requisite for considering CRT. § Drugs that were shown to modify HF hospitalizations and mortality in randomized controlled trials: beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, sacubitril/valsartan, mineralocorticoid receptor antagonists, and ivabradine. the estimated cumulative dose to CIED should be limited. ECG monitoring should be available during radiotherapy sessions for pacemaker-dependent patients. 52 Cardiac imaging should follow irradiation to the chest, e.g. in lymphoma or breast cancer, in long-term intervals. 53 Awareness of the possible problems when administering anti-cancer treatments to HF patients should not lead to therapeutic inertia with omission of potentially life-saving cancer drugs. The detrimental impact of this approach was demonstrated in over 5000 patients with locally advanced colorectal cancer, in which subjects with concomitant HF were 50% less likely to receive adjuvant chemotherapy than those without HF. However, once started, chemotherapy was completed with a similar frequency and conferred a comparable improvement in survival in the two subgroups, suggesting that it was underutilized in the presence of HF. 
Risk of down-titrating or abandoning heart failure-specific drugs
First, it may not be possible to maintain the optimal medical therapy for HFrEF. This includes high doses of a beta-blocker with either an ACE inhibitor, an angiotensin receptor blocker or an angiotensin receptor/neprilysin inhibitor, and a mineralocorticoid receptor antagonist. 1 Diuretics are also frequently required, and ivabradine may be added if the HF patient is in sinus rhythm with an elevated resting heart rate. Experience suggests that this complex treatment is often simplified, with dose reduction or even drug interruption, when performance and health status deteriorate due to malignancy or when anti-tumour drugs are administered. There are several explanations for this behaviour, such as hypotension, electrolyte depletion and acutely worsening renal function caused by vomiting and/or diarrhoea, which are common in patients with advancing cancer or receiving chemotherapy. Eventually, cessation of drugs inhibiting the renin-angiotensin-aldosterone axis is often required. Nonetheless, longitudinal studies specifically investigating this scenario are lacking. The safety of spironolactone in hormone-sensitive malignancies has not been clearly established, and it is best avoided in women with oestrogen receptor-and/or progesterone receptor-positive breast cancers; we believe that in these patients eplerenone is a suitable alternative. 55 
The conundrum of anticoagulation
Atrial fibrillation is a common complication of HF 56 as well as of cardiotoxic chemotherapy, and should be considered when symptoms and signs of decompensation develop. Direct oral anticoagulants are now recommended for the prevention of arterial thromboembolism associated with atrial fibrillation, given their more favourable risk-benefit profile compared with the one of warfarin. 57 This holds true for patients with HF, in whom direct anticoagulants have been confirmed to have equal or superior efficacy, while being safer than warfarin. 58 HF patients with cancer also face a substantial risk of deep vein thrombosis, pulmonary embolism and central venous catheter-associated thrombosis, collectively defined as venous thromboembolism. In this context, the long-term safety and efficacy of direct oral anticoagulants are not known and are currently being tested in several ongoing randomized controlled trials. 31 Until the results of these studies are available, low molecular weight heparin remains the drug of choice for prophylaxis or treatment of cancer-related venous thromboembolism. 59 Thus, cardiologists and oncologists face the conundrum of which anticoagulation strategy is preferable for patients with pre-existing HF and atrial fibrillation who develop cancer and are at risk of neoplastic venous thromboembolism. In addition, there is concern about the consequences of possible drug interactions between direct anticoagulants and anti-cancer therapies, since patients taking the latter ones have not been included in either clinical trials or observational registries.
31,59

Utilization of devices and advanced therapies
In the setting of HF, cancer may represent a contraindication to eligibility for device therapy (Figure 2) . Implantable cardioverter-defibrillator (ICD) implantation may be withheld if life expectancy is predicted to be shorter than 1 year.
1 Nevertheless, decisions regarding eligibility for ICD should be kept under review as patients with substantial responses to modern targeted anti-tumour therapies may have prolonged progression-free survival and may merit ICDs if the competing risk of sudden cardiac death is high. This possibility is hardly predictable at present, and fuels the ongoing debate on which patients are most likely to benefit from ICD in primary prevention. A recent analysis of a Danish nationwide registry indicates that there has been a trend over the last years to use ICD for primary prevention in patients with more co-morbidities, who however are more likely to die without any appropriate ICD therapy. 60 Active cancer with a life expectancy <2 years is also an absolute contraindication for mechanical circulatory support with a left ventricular assist device (LVAD) as both bridge to heart transplantation and destination therapy. 61 61 It must be noted that the level of evidence supporting this statement is low (class C). In fact, a history of cancer was associated with death or persistent HF symptoms and poor quality of life in patients from the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) registry who received a LVAD for destination therapy or bridge to transplantation, but with low likelihood of being actually transplanted. 62 Discussion with the oncologist is key, as prognosis may be surprisingly good for some patients with treatment-responsive cancers even if metastatic at presentation.
Post-transplant immunosuppression also poses a risk of malignancy recurrence, which is related to the duration of cancer-free survival before organ transplantation. 63 Therefore, past cancer does not necessarily preclude access to cardiac transplantation, possibly bridged by mechanical support. 61, 64 By contrast, current malignancy, other than localized non-melanoma skin cancer, is an absolute exclusion from cardiac transplantation. 64 Cases have been described of patients who were implanted with a LVAD in spite of being diagnosed with cancer during the pre-implantation screening, underwent tumour resection after haemodynamic improvement due to the mechanical support, and finally were transplanted. 65, 66 This scenario is rare, but highlights the challenge for the timing of cardiac and oncological therapies when cancer is discovered in a patient with pre-existing advanced HFrEF.
Conclusions and gaps in knowledge
Cancer diagnosis is not an uncommon event in patients with HF and carries important implications in terms of prognosis and both cardiac and anti-tumour treatment. A close collaboration between cardiologists and oncologists is fundamental to improve the management of these patients, with both specialists understanding the benefits of therapy for HF and cancer, and the risks of withholding or sub-optimally treating either or both diseases. 34 The prognostic impact of each condition should always be well defined and considered in decision-making. A multidisciplinary approach is encouraged and should include other healthcare professionals, including cardiac rehabilitation, psychology and palliative care where necessary.
The scientific evidence upon which clinical decisions can be based is very limited, but epidemiology is showing that occurrence of cancer in HF is an increasingly common problem with an ageing population and in the current era of cancer and post-myocardial infarction survivorship. The SAFE-HEaRt trial has recently been designed to test whether anti-HER2 drugs may be safely administered to patients with mildly reduced cardiac function in the setting of ongoing cardiac treatment. 67 Further well-designed studies are required to clarify the thresholds at which cancer treatment should not be administered to patients with pre-existing HF, and the optimal cardioprotective and surveillance strategies for patients in whom these two serious conditions coexist. 
